Sexual health is an essential aspect of overall wellbeing for people of all gender identities. For transgender women, transfeminine individuals, and non-binary people assigned male at birth (AMAB), maintaining safe sexual practices, understanding HIV risk, and accessing appropriate healthcare services are key components of long-term health.
Transfeminine is commonly used to describe individuals assigned male at birth who identify with femininity or a feminine gender identity.
Protection During Sexual Activity
Sexually transmitted infections (STIs) can affect anyone, regardless of gender identity or sexual orientation, and can be transmitted through various forms of sexual contact.
Health experts recommend regular STI screening at least annually for sexually active individuals to support early detection and reduce transmission risk.
Barrier methods remain the most effective protection against STIs. These include:
- External condoms, used over a penis or sex toy
- Internal condoms, used inside the vagina or rectum
- Dental dams, used during oral sex or rimming
Condoms should be replaced between different types of sexual activity or after extended use. Consistent use is recommended regardless of whether an individual has undergone gender-affirming genital surgery.
Lubricants may also be used to reduce friction and prevent tissue damage. Water-based and silicone-based lubricants are generally compatible with latex condoms, while oil-based products can weaken them. Silicone-based lubricants should be used cautiously with silicone sex toys to avoid surface damage.
Sexual Health After Gender-Affirming Surgery
Gender-affirming genital surgery may affect sexual health risks and care needs. According to sexual health organizations, healing tissue after surgery may be more vulnerable to infection until fully recovered.
Some surgical procedures, such as colovaginoplasty (using intestinal tissue to construct a vagina), may carry different infection risks compared to procedures using penile or scrotal tissue.
Healthcare providers typically advise patients to avoid sexual activity during recovery and to follow individualized guidance on resuming intercourse.
Post-surgical sexual health recommendations may include:
- Using lubricants to reduce friction and prevent injury
- Following dilation protocols when prescribed
- Using condoms when STI status is unknown
Contraception and Hormone Therapy
Transgender women who have not undergone procedures such as vasectomy or orchiectomy may still require contraception if engaging in vaginal sex with partners who can become pregnant.
Gender-affirming hormone therapy including medications such as estradiol, GnRH analogues, finasteride, or cyproterone acetate does not provide reliable contraceptive protection.
Clinicians advise that pregnancy prevention should be considered separately from hormone-based treatments.
HIV Risk in Transfeminine Communities
Research from the Centers for Disease Control and Prevention indicates that transgender women face a disproportionately high risk of HIV infection compared with the general population.
Studies show significant disparities across racial and ethnic groups, with particularly high prevalence among Black and Hispanic transgender women in some urban areas.
Public health experts attribute these disparities to multiple intersecting factors, including:
- Discrimination in healthcare and employment
- Barriers to housing and economic stability
- Limited access to gender-affirming care
- HIV-related stigma
- Gaps in provider knowledge of transgender health needs
Routine HIV testing is recommended for sexually active individuals, especially those with multiple partners or other risk factors.
HIV Treatment and Outcomes
HIV is treatable with antiretroviral therapy (ART), which suppresses viral replication and allows individuals to live long, healthy lives.
When taken consistently, ART can reduce viral load to undetectable levels, effectively preventing sexual transmission of the virus.
Healthcare providers also monitor potential interactions between HIV medications and gender-affirming hormone therapy to ensure safe and effective treatment.
PrEP: HIV Prevention Before Exposure
Pre-exposure prophylaxis (PrEP) is a preventive medication used by HIV-negative individuals to reduce the risk of infection.
Approved by the U.S. Food and Drug Administration, PrEP is available in daily or event-based dosing regimens depending on individual risk and clinical guidance.
PrEP is commonly considered for individuals who:
- Have partners with unknown or positive HIV status
- Do not consistently use condoms
- Engage in sex work
- Inject drugs or share injection equipment
- Have recently had another STI such as syphilis or gonorrhea
Studies indicate that PrEP can be safely used alongside gender-affirming hormone therapy without reducing hormone effectiveness.
PEP: Emergency HIV Prevention
Post-exposure prophylaxis (PEP) is a short-term treatment used after potential HIV exposure.
PEP must be started within 72 hours of exposure, with the greatest effectiveness when initiated within 24 hours. It is typically taken for 28 days under medical supervision.
Access to Transgender-Inclusive Care
Access to sexual health services varies widely, but many regions offer clinics and resources specifically designed to support transgender patients.
Transgender-friendly healthcare services can often be located through national public health resources, including listings provided by the Centers for Disease Control and Prevention.
Summary
Transgender women and transfeminine individuals face unique sexual health considerations, including higher HIV risk and barriers to healthcare access. However, consistent use of barrier protection, routine testing, and preventive options such as PrEP and PEP can significantly reduce health risks.
With appropriate medical support and inclusive healthcare systems, individuals can effectively manage sexual health while reducing the risk of STIs and HIV transmission.
